Search Results for: crosswise

67 innovative startups to celebrate Israel’s 67th anniversary

67 innovative startups to celebrate Israel’s 67th anniversary

Apr 23, 2015 | ,

Today, Israel celebrates 67 years of the Startup Nation. People around the world are paying attention as this story continues to unfold – a startup country with a startup mentality, creating amazing innovation across all ‘sectors’ of life. And today, OurCrowd also announces the launch of our 67th investment! In just two short years, OurCrowd has established itself as a major force in startup investing, with more than $110M invested from its community of thousands of accredited investors from around the world. OurCrowd’s companies span major investment sectors – and even continents –  and include innovation in the Internet of Things, Fintech, Cybersecurity, Medtech, Agritech, Big Data, and Robotics. So, without further ado, here are OurCrowd’s 67 investments and portfolio companies: Consumer Hardware/Internet of Things BT9 – IoT for supply chain management. Clipfort – Securing firearms with biometric authentication. Consumer Physics – Makers of Scio, the molecular scanner that has been hailed as “Google for matter,” with a top ten Kickstarter campaign. Corephotonics – A compact camera design house with computational photography expertise. Stringify – Unifying platform for the Internet of Everything. MUV Interactive – Making any surface a...

Read More

PRESS RELEASE: OurCrowd Marks Israel’s 67th Anniversary with Addition of 67th Portfolio Company

Apr 21, 2015

MATERIALS FOR RELEASE: PDF download here Photos and logos ZIP file download here — OurCrowd Marks Israel’s 67th Anniversary with Addition of 67th Portfolio Company OurCrowd Adds Innovative Brain Company ElMindA to its Growing List of Israeli Startups Jerusalem, Israel, April 22, 2015 –  OurCrowd, the world’s leading equity crowdfunding platform, is marking Israel’s 67th birthday with the announcement of its 67th portfolio company, ElMindA. Named one of the 50 most innovative companies worldwide, ElMindA has developed the world’s first FDA-approved neural functional assessment tool to visualize serious brain trauma and illnesses. The technology is potentially a huge breakthrough for mitigating sports injuries, advancing brain research and changing the lives of the two billion people worldwide living with brain disorders. In just two short years, OurCrowd has established itself as a major international force in the equity crowdfunding industry, investing over $110M from its “crowd” of thousands of accredited investors in its portfolio companies, which span major investment sectors including the Internet of Things, Fintech, Cybersecurity, Medtech, Agritech, Big Data, and Robotics. “OurCrowd has become the most active investor in the Israeli tech sector over the...

Read More
Where We’ve Been: A review of OurCrowd’s global events during Q1 2015

Where We’ve Been: A review of OurCrowd’s global events during Q1 2015

Apr 16, 2015 | ,

It’s been a busy few months at OurCrowd! Throughout January, February, and March of 2015, OurCrowd hosted numerous events worldwide, including our annual Passover breakfast event in the beginning of April (we had to sneak it in here!), and we’re taking a moment to review where we’ve been and who we invested in, and learn where we’ll be next quarter. We’re so proud of what the OurCrowd community has accomplished over the past three months — from events hosted to the companies funded — and are looking forward to continuing this journey together in the months to come. Without further ado, here is a glimpse into all the excitement happening at OurCrowd: Where We’ve Been Over the past three months, OurCrowd founder & CEO Jon Medved and team members have traveled the world, hosting various events with the CEOs of our latest startups and guest speakers. We’ve held a total of 48 events, in 22 cities (from 6 different countries), across 5 continents! In case you missed them, here are some event highlights: January 4th – Kicking off the quarter, OurCrowd hosted a panel discussion...

Read More
How do I make money investing in startups?

How do I make money investing in startups?

Jan 25, 2015 |

I wish investing in a startup was as easy as “buy low, sell high“, but it’s a bit more complex. Angel investors must consider a variety of factors when they put their capital to work in an early stage company like: Startup valuation: Figuring out how much a startup is worth is as much an art as it is a science. Choosing the right founders: Team plays a critical role in a startup’s success. Investors want to invest in successful founders. Portfolio management: What’s the right number of startups to hold in a portfolio? (Hint: Kauffman Foundation research says at least 6). Taxes: You gotta pay Uncle Sam at some point, right? and lots more…  With all this in mind, a startup investor has to juggle lots of things at once — but ultimately, it’s all about the money. How do I make money investing in startups? As OurCrowd and other equity crowdfunding startups democratize early stage investing, we get asked a lot about how investors make money in startups. Basically, there are 4 ways a startup investor can...

Read More
What We’re Investing In: Current investment opportunities on OurCrowd (January 2015)

What We’re Investing In: Current investment opportunities on OurCrowd (January 2015)

Jan 22, 2015 | , , ,

OurCrowd’s portfolio growth is expanding: this month, featured opportunities include innovative companies in the medical technology and cyber security spaces. Stay tuned – there are more deals to be announced before the end of the month; bookmark this post to view the next deals. TheraCoat: Hydrogel-based drug delivery A major pain point for pharmacologists when developing drugs is finding a substance that can efficiently deliver the needed medication before the body’s natural fluids wash it away. TheraCoat’s Intracavity Drug Retention System (ICDR) was created to solve that very problem. Their patent-protected substance liquefies when in cool temperatures and hardens in hot temperatures. The ICDR is mixed with the necessary drug and taken in liquid form. When the liquid reaches the cavity, body heat causes the substance to harden and stick to the walls of the cavity. This enables the drug to be emitted at a slow, consistent rate, without being washed away by the body’s fluid. So far, TheraCoat has experienced significant early traction, conducting a number of successful test trials and securing regulatory clearance in a number of...

Read More